SYNDAX PHARMACEUTICALS
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
SYNDAX PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.syndax.com
Total Employee:
101+
Status:
Active
Contact:
(185) 879-2799
Total Funding:
803.58 M USD
Technology used in webpage:
Domain Not Resolving Google Font API Google Google Cloud JQuery CDN Vimeo Google Cloud Global Multi-Region New Relic Mobile Optimized Drupal
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Peter Ordentlich Chief Scientific Officer and Founder @ Syndax Pharmaceuticals
Chief Scientific Officer and Founder
2013-11-01
Keith A. Goldan Chief Financial Officer @ Syndax Pharmaceuticals
Chief Financial Officer
2022-06-01
Daphne Karydas CFO @ Syndax Pharmaceuticals
CFO
2020-07-01
Matthew G. Nerney CIO @ Syndax Pharmaceuticals
CIO
2017-10-01
Kate Madigan CMO @ Syndax Pharmaceuticals
CMO
2022-03-01
Steven Closter Chief Commercial Officer @ Syndax Pharmaceuticals
Chief Commercial Officer
2024-03-01
Briggs Morrison President, Head of Research & Development @ Syndax Pharmaceuticals
President, Head of Research & Development
2022-02-01
Luke Albrecht General Counsel and Secretary @ Syndax Pharmaceuticals
General Counsel and Secretary
2016-08-01
Michael Metzger CEO @ Syndax Pharmaceuticals
CEO
2022-01-01
Suniket Fulzele Director, Pharmaceutical Development and Manufacturing @ Syndax Pharmaceuticals
Director, Pharmaceutical Development and Manufacturing
2020-07-01
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Syndax Pharmaceuticals
AI Life Sciences Investments LLC
AI Life Sciences Investments LLC investment in Post-IPO Debt - Syndax Pharmaceuticals
Boxer Capital
Boxer Capital investment in Post-IPO Debt - Syndax Pharmaceuticals
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Debt - Syndax Pharmaceuticals
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Debt - Syndax Pharmaceuticals
OrbiMed
OrbiMed investment in Series C - Syndax Pharmaceuticals
RMI Partners
RMI Partners investment in Series C - Syndax Pharmaceuticals
BioMed Ventures
BioMed Ventures investment in Series C - Syndax Pharmaceuticals
Delos Capital
Delos Capital investment in Series C - Syndax Pharmaceuticals
Tavistock Life Sciences
Tavistock Life Sciences investment in Series C - Syndax Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.syndax.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.69 K
Unable to get host informations!!!
More informations about "Syndax Pharmaceuticals"
Syndax Pharmaceuticals - Crunchbase Company Profile …
Organization. Syndax Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
About Us - Syndax
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for …See details»
Syndax Pharmaceuticals Inc - AnnualReports.com
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Company lead product candidate, entinostat, …See details»
Syndax Pharmaceuticals Announces Transition of Michael A.
Feb 3, 2022 "Briggs and I have worked very closely in partnership over the last seven years to expand Syndax's portfolio of assets through business development transactions while …See details»
Syndax Announces Appointment of Steven Closter as Chief …
Mar 18, 2024 "Syndax is at a pivotal moment, with the expected delivery of two first- and best-in-class therapies this year to people living with cancer. I look forward to leading the continued …See details»
Our Products - Syndax
To report an adverse event or product quality complaint for Revuforj ® (revumenib), or to request additional medical information, contact medinfo@syndax.com or call 1-888-539-3REV (3738), option 1 SyndAccess™ …See details»
What is Syndax Pharmaceuticals? Company Culture, Mission, Values
See what employees say it's like to work at Syndax Pharmaceuticals. Salaries, reviews, and more - all posted by employees working at Syndax Pharmaceuticals. ... Syndax has been ranked as …See details»
Great Organization and Even Greater People - Glassdoor
Committed to improving the lives of patients and families affected by cancer, employees are well versed in the oncology space as well as genuinely invested in their work and the greater …See details»
Syndax Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Syndax Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Number of Board Member and Advisor …See details»
Corporate Presentation / May 2024 - Syndax Pharmaceuticals, Inc.
Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes …See details»
Syndax Pharmaceuticals - Funding, Financials, Valuation & Investors
Syndax Pharmaceuticals is registered under the ticker NASDAQ:SNDX . Syndax Pharmaceuticals is funded by 20 investors. Hercules Capital and AI Life Sciences Investments LLC are the …See details»
Careers - Syndax
At Syndax, we are reimagining how cancer is treated with a dedication to advancing first-in-class solutions that provide meaningful and differentiated clinical results and address urgent unmet …See details»
Syndax Pharmaceuticals (SNDX) Earnings Date and Reports 2025
2 days ago Syndax Pharmaceuticals announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.98, which topped analysts' consensus estimates of -$1.13 by $0.15. …See details»
Syndax Announces FDA Approval of Revuforj® (revumenib), the …
Nov 15, 2024 – Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a …See details»
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call …
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsSharon Klahre - Head, Investor...See details»
Leadership Team - Syntax
Prior, he managed ERP projects globally and led a technical consulting organization. With over two decades in technology, Marcelo emphasizes empowering individuals to provide …See details»
Compassionate Use - Syndax
The physician who requests access must be qualified, agree to directly supervise treatment, be willing to obtain relevant health authority approval/clearance, otherwise comply with relevant …See details»
Syndax Pharmaceuticals - Syndax: The Pinnacle of Workplace …
Innovative Environment: Syndax is at the forefront of cancer treatment, constantly pushing the boundaries of medical science. Impactful Work: Every task contributes to developing life …See details»
Indigenous Financial & Administration Software and Financial …
Xyntax Group works with Indigenous organizations and First Nations across Canada, providing integrated software solutions, like INEXSUITE and Finance and Management Services to …See details»
Privacy Notice - Syndax
Aug 7, 2024 Syndax Pharmaceuticals, Inc. (”Syndax”, “our”, “we” or “us”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your …See details»